References
- Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheu-matoid arthritis. Arthritis Rheum. 1992;35:729–35.
- Yocum DE, Pincus T, Choy EHS, Scott DL, Richardson C, Emery P, et al. Cyclosporin in the treatment of severe rheumatoid arthritis and the emerging role of a microemulsion-based for-mulation (Neoral°). Drugs. 1995;50\(Supp1.1).
- Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S, et al. FK506 potently inhibits T cell activation-induced TNF-a and IL-1/3 production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130:1655–63.
- Inamura N, Hasimoto M, Nakahara K, Aoki H, Yamaguchi I, Kohsaka M. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol. 1988;46:82–90.
- Miyahara H, Hotokebushi T, Arita C, Arai K, Sugioka Y, Tak-agishi K, et al. Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. Clin Immunol Immunopathol. 1991;60: 278–88.
- Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol. 2003;30:2193–200.
- Hara M, Sugawara S, Hirose S, Uchida S, Irimajiri S, Kondo H, et al. Therapeutic effects of FK506 on patients with rheumatoid arthritis (in Japanese). Inflamm Regen. 2002;22:213–26.
- Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double-blind, placebo-con-trolled dose-finding study. J Rheumatol. 2004;31:243–51.
- Kawai S, Yamamoto K. Safety of tacrolimus, an immunosup-pressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology. 2006;45:441–4.
- Kawai S, Hashimoto H, Kondo H, Murasawa T, Kiuchi T, Abe T. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:2153–61.
- Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology. 2004;43:992–9.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
- Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology pre-liminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36:729–40.
- Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology pre-liminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–35.
- Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402–11.
- Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52:412–20.
- Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a pop-ulation-based study. Arthritis Rheum. 2005;52:722–32.
- Singh N, Bonham A, Fukui M. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. Transplan-tation. 2000;69:467–72.